CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Tumor Microenvironment: A Niche for Cancer Stem Cell Immunotherapy.
Tumor Microenvironment: A Niche for Cancer Stem Cell Immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
致瘤性癌症干细胞(CSC),常称为肿瘤起始细胞(TIC),是肿瘤环境中一类独特细胞。其自我更新、转移和分化能力突出,因此区别于大部分肿瘤细胞。尽管CSC分类研究取得进展,这类细胞仍对常规放疗和化疗表现出显著耐受,导致癌症复发。本文旨在探讨CSC在周围肿瘤微环境(TME)中的独特特征及其相关新兴研究方向。文章首先概述CSC的定义性特征,随后深入讨论其与淋巴系细胞(包括T细胞、B细胞和NK 细胞)的复杂相互作用,并介绍其与髓系细胞(包括巨噬细胞、中性粒细胞和髓源性抑制细胞[MDSC])的动态联系。此外,本文阐述CSC与间充质来源细胞(特别是成纤维细胞、脂肪细胞和内皮细胞)之间的相互作用,并强调CSC在肿瘤相关细胞外基质(ECM)中的关键作用。最后,文章综述在复杂TME环境中靶向CSC的临床前和临床研究,包括CAR-T 疗法、溶瘤病毒和CSC疫苗,旨在发现基于CSC的癌症免疫治疗新方向。
Tumorigenic Cancer Stem Cells (CSCs), often called tumor-initiating cells (TICs), represent a unique subset of cells within the tumor milieu. They stand apart from the bulk of tumor cells due to their exceptional self-renewal, metastatic, and differentiation capabilities.
Despite significant progress in classifying CSCs, these cells remain notably resilient to conventional radiotherapy and chemotherapy, contributing to cancer recurrence. In this review, our objective is to explore novel avenues of research that delve into the distinctive characteristics of CSCs within their surrounding tumor microenvironment (TME).
We will start with an overview of the defining features of CSCs and then delve into their intricate interactions with cells from the lymphoid lineage, namely T cells, B cells, and natural killer (NK) cells.
Furthermore, we will discuss their dynamic interplay with myeloid lineage cells, including macrophages, neutrophils, and myeloid-derived suppressor cells (MDSCs).
Moreover, we will illuminate the crosstalk between CSCs and cells of mesenchymal origin, specifically fibroblasts, adipocytes, and endothelial cells. Subsequently, we will underscore the pivotal role of CSCs within the context of the tumor-associated extracellular matrix (ECM).
Finally, we will highlight pre-clinical and clinical studies that target CSCs within the intricate landscape of the TME, including CAR-T therapy, oncolytic viruses, and CSC-vaccines, with the ultimate goal of uncovering novel avenues for CSC-based cancer immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。